JPRN-UMIN000051448RecruitingUnknown
Oral semaglutide vs DPP-4i on body weight in Japanese people with type 2 diabetes - OSCAR-DWD study
Dokkyo Medical University Department of Endocrinology and Metabolism0 sites70 target enrollmentStarted: June 26, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other GLP-1R analogue 8)Patient with intolerance of medical reasons by doctor.
Investigators
Similar Trials
Completed
Not Applicable
Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2Type 2 diabetesJPRN-UMIN000020239Shiga University of Medical Science52
Not yet recruiting
Phase 3
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®ObesityNCT06633783Hangzhou Jiuyuan Gene Engineering Co. Ltd.,370
Completed
Phase 4
SUMS-ADDIT-2Type 2 Diabetes MellitusJPRN-jRCTs051180018Morino Katsutaro52
Completed
Not Applicable
Effects of Ipragliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin TherapyType 2 diabetesJPRN-UMIN000018839Shiga University of Medical Science50
Completed
Phase 3
Effect and safety of NN9535 in weight management (NN9536-4382)JPRN-jRCT2080224531ovo Nordisk Pharma Ltd.401